Fig. 1: Genetic alterations of MVA pathway-related enzymes across urologic tumors.

a Mutation frequency of MREs across cancers in TCGA database. The X-axis represents each cancer, and the Y-axis represents the frequency of mutations in MREs. The data were downloaded from the Xena Browser (https://xenabrowser.net/). b Mutation types, mutation frequencies and tumor mutation burden (TMB) of MREs across cancers. The X-axis represents each cancer, the Y-axis represents the different MREs and the number of samples with mutations, and the top is the TMB. c Histogram shows the frequency of SCNAs for each MRE in each cancer type. d The gene expression patterns of MREs across cancers. The X-axis represents each cancer, the Y-axis represents the different MREs, and the top represents the statistics of the number of upregulated and downregulated MREs in different types of tumors. e The Spearman’s correlation between somatic copy number alterations and the expression of MREs. MPIs were validated in multiple datasets: GSE2450 (f), GSE252007 (g), GSE40355 (h), GSE3167 (i), and TCGA-BLCA (j). Survival analysis of BLCA patients with high MPI or low MPI from the TCGA dataset (k) and GSE13507 dataset (l). Statistical significance was ascertained by two-tailed unpaired Student’s t-tests (g–j) and the log-rank test of Kaplan–Meier analysis (k and l). The data are shown as the means ± SD. BLCA bladder urothelial carcinoma, KICH kidney chromophobe, KIRC kidney renal clear cell carcinoma, KIRP kidney renal papillary cell carcinoma, PRAD prostate adenocarcinoma.